Reach Us +1-217-403-9671
Overview Of Generic Drugs Review Process | 7497
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Overview of generic drugs review process

2nd International Conference and Exhibition on Pharmaceutical Regulatory Affairs

Durgacharan A. Bhagwat and John I. D?Souza

Accepted Abstracts: Pharmaceut Reg Affairs

DOI: 10.4172/2167-7689.S1.008

The Office of Pharmaceutical Science (OPS) is an integral part of the FDA Center for Drug Evaluation and Research (CDER) new and generic drug product application review process. The office provides uniform policies and review processes for the pharmaceutical industry. A generic drug product is one that is comparable to an innovator drug product in dosage form, strength, route of administration, quality, performance characteristics and intended use. The OPS laboratory programs support efforts to determine the correct quality standards, and in certain cases, validate the information companies provide. Drug companies, as part of the new drug approval, provide FDA with a list of relevant patents. FDA publishes the patent information and refers generic companies to review patents as part of the research and development process. FDA awards 180 days of exclusivity to the first generic holder to file a complete application (ANDA) with a patent challenge. This exclusivity does not apply against the brand company already in the marketplace but provides protection from other generic competition. FDA has some special issues in the generic review process: consistency among reviews of multiple applications, fairness and timing of reviews, patent and exclusivity issues and demonstration of bioequivalence. The value of generics is the reduction in cost. FDA knows that if a drug costs less, it increases use and prevents shortages resulting from product rationalization or supply disruption. Ultimately, FDA wants consumers to feel confident. Brand or generic, the consumer is getting a FDA-approved product that is interchangeable.
Durgacharan Arun Bhagwat M. Pharm.(Industrial Pharmacy): completed UG from Shivaji University, Kolhapur and PG from SGB Amravati University and pursuing Ph.D. from JJT University, Rajasthan, presently working as Asst. Professor Dept. of Pharmaceutics, Tatyasaheb Kore College of Pharmacy, Warananagar. He has 4 yrs of teaching experience. He published 1 Book and 14 research papers in reputed National and International journals and also presented 40 papers at various national and international conferences. He is Life Member of Indian Pharmaceutical Association (IPA) and Associate Life member of Indian Hospital Pharmacist Association (IHPA). He is Hon. Secretary of IPA Kolhapur Local Branch. He is Executive editor of International Peer reviewed journal ?Pharmacum Consequat?.